Category: pharma & healthcare

Merck Seeks A `Fair’ Drug Price In Lawsuit Against Inflation Reduction Act, But So Does Medicare: Neither Price Is Fair

Merck seeks a fair drug price in lawsuit against the IRA, but so does Medicare. Neither price Is fair. Merck and Medicare use notions of fairness untethered to value.

Breaking The Sound Barrier: The FDA’s Approval Of Over-The-Counter Hearing Aids

The FDA’s approval of over-the-counter hearing aids will improve financial and accessibility conditions for the hearing impaired.

Might Hepatitis D Virus Cause More Diseases Than Initially Thought?

Hepatitis D virus depends on a helper virus to enter host cells. Hepatitis B virus was long considered its sole helper. Novel research suggests otherwise.

Is A Broadly Protective And Long Lasting Hepatitis C Vaccine Possible?

Current understanding of the hepatitis C virus requires that a vaccine be both broadly protective and long lasting.

To Kill And Kill Again: How Cytotoxic T Cells Attack Target After Target

Research using high resolution, three dimensional imaging reveals new insights on how killer T cells swiftly kill target after target.

She DOES Survive: Grammy-Winner Gloria Gaynor Battles Self-Doubt & Surgeries With Spirituality & Self-Love

Disco legend Gloria Gaynor overcomes sexual abuse, divorce, financial struggles and major spinal surgery in new documentary film at Tribeca Festival.

The Road To CRISPR Vision

Stem cell therapies have been making significant progress in restoring vision loss. Here we describe recent advances that use CRISPR to treat retinitis pigmentosa.

Molecular Acrobatics: A Look At Hepatitis D Virus Replication

Hepatitis D virus hijacks host cell transcription machinery to make copies of its genetic code. Here, we take a look at the steps involved in this process.

Beyond Paralysis: Advances In Brain-Spine Interfaces For Post-Injury Movement Restoration

The latest advances in brain-spine interface technology may help those with impeded lower body motor functions to walk again.

U.S. Market For New Wave Of Obesity Drugs Is Much Bigger Than Europe’s For Many Reasons

The U.S. market for new obesity drugs is much larger than Europe’s. Substantially lower obesity prevalence in Europe is an obvious reason. But there are many others.